Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure.
Pooled data from trials comparing nesiritide with dobutamine for treatment of acute decompensated congestive heart failure were combined with national hospital cost data in an economic model. Results indicate that the acquisition cost of nesiritide is fully offset by decreased hospital costs.
de Lissovoy
Gregory
G
MEDTAP International, Inc, Bethesda, Maryland 20814, USA. delissovoy@medtap.com
Stier
David M
DM
Ciesla
Gabrielle
G
Munger
Mark
M
Burger
Andrew J
AJ
D000208:Acute Disease; D017677:Age Distribution; D000368:Aged; D002316:Cardiotonic Agents / Q000191:economics* / Q000627:therapeutic use*; D004280:Dobutamine / Q000191:economics* / Q000627:therapeutic use*; D016527:Drug Costs / Q000706:statistics & numerical data; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality; D017721:Hospital Costs / Q000706:statistics & numerical data*; D006801:Humans; D008017:Life Expectancy; D008297:Male; D008875:Middle Aged; D017059:Models, Econometric; D009010:Monte Carlo Method; D045283:Natriuretic Agents / Q000191:economics* / Q000627:therapeutic use*; D020097:Natriuretic Peptide, Brain; D010343:Patient Admission / Q000191:economics; D011237:Predictive Value of Tests; D017678:Sex Distribution; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D026712:Value of Life
D002316:Cardiotonic Agents; D045283:Natriuretic Agents; D020097:Natriuretic Peptide, Brain; D004280:Dobutamine